About the Study

Chikungunya is an illness caused by a virus that spreads through mosquito bites, similar to other mosquito spread illnesses like Zika, malaria, dengue and West Nile Virus. If you are bit by an infected mosquito with chikungunya, you will develop symptoms in 3-7 days. The most common symptoms of infection are fever and joint pain. Others also experienced headaches, muscle pain, joint swelling or a rash. While the disease does not frequently result in death, many of the symptoms can be severe or disabling for several months or years after symptoms develop. Currently, there is no vaccine to prevent or medicine to treat chikungunya virus infection.

While mosquitoes infected with Chikungunya today are more prevalent in countries in Africa, Asia, Europe and the Indian and Pacific oceans, there is a risk that the virus will be imported to new areas by infected travelers. In 2014, the first chikungunya virus disease cases were reported among US travelers returning from affected areas and local transmission was identified especially in Florida, Puerto Rico and the US Virgin Islands.

Rochester Clinical Research is participating in a study evaluating the immune response of a single dose of the study Chikungunya vaccine in healthy adults over the age of 18 years old.  The study will be able to measure the antibodies in your blood to see if you would be protected against the virus. The vaccine will hopefully be used for those living in an infected area, or people who will travel to Chikungunya infected areas.  The study will last approximately 13 months with 7 visits to our office. Compensation is available for time and travel, for those who qualify.

Qualifications

  • Over the age of 18 years old
  • Generally Healthy
  • Have not had a Chikungunya infection in the past 6 months
  • Please note, other conditions may apply